Your Go-To Laboratory CRO for global COVID-19 Analytical Services
With more than 2,800 registered clinical trials worldwide for the treatment and diagnosis for COVID-19, Eurofins is your go-to partner in support of global Vaccine Trials and Therapeutic Research.
In collaboration with Eurofins Biopharma Services group (Eurofins CDMO Clinical Trial Supply and Eurofins Central Laboratory) as well as external solution providers, Eurofins is able to support Direct To Subject visits with:
a) Direct To Subject Investigational Product distribution
b) Direct to Subject study specific specimen collection kits, in coordination with Home Visit Nursing services.
In addition, with challenges being experienced worldwide with global supply chains and courier logistics routes, Eurofins is able to provide assistance in both categories.
a) We are currently stocked with subject collection kit materials and can ship all necessary collection supplies to your locations globally.
b) With the significant global volume of courier services utilized annually by Eurofins, we have preferred status with numerous transport companies, allowing prioritization of your specimens.
Since the emergence of the Covid-19 global outbreak, Eurofins Central Laboratory clinical testing sites and Kit Packing & Distribution sites have been open and operating at normal global capacity to provide critical clinical trial testing.
Eurofins scientists develop multiple new solutions to support the world’s fight against the COVID-19 pandemic – ramping up production to enable over 20 million patients tests per month by end May 2020 Activity shows strong resilience in Q1 2020 – April 28, 2020
Eurofins Genomics U.S. launches new SARS-CoV-2 plasmid DNA controls and increases its capacity to produce probes and primers, all of which being key components of SARS-CoV-2 RT-PCR testing – April 14, 2020
Eurofins Scientific Supports Healthcare Authorities in Europe, the U.S.A. and Brazil in their Fight against the COVID-19 Pandemic with Additional Testing Options and Fast Growing Capacity – March 19, 2020